{
  "schema_version": "chamgap-public-criteria-1.0",
  "title": "Single-ingredient oral vitamin C × Relief of nasal symptoms in allergic rhinitis",
  "language": "en",
  "translation_date": "2026-10-23",
  "criteria_version": "1.0",
  "criteria_date": "2026-10-06",
  "condition_origin": "Chamgap's own application conditions",
  "method_sources": [
    {
      "id": "M03",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03",
      "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13",
      "official_principle": "Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M04",
      "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04",
      "section": "§4.5, §4.6.1–4.6.3, MECIR C42",
      "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results are unreported.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M08",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08",
      "section": "§8.1–8.2.3, Table 8.2.a",
      "official_principle": "Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M15",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15",
      "section": "§15.2.4, §15.3.1–15.3.3",
      "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M19",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19",
      "section": "§19.1.2, §19.2.1–19.2.4",
      "official_principle": "Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    }
  ],
  "status_dictionary": {
    "Partly verified": "Partial information from the stored summary is linked; detailed originals and content review remain incomplete.",
    "Unverified": "Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.",
    "Review incomplete": "Review of existing content remains incomplete.",
    "Met": "This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.",
    "Not reported": "Unreported within material actually read. Unread external material is not relabeled as unreported.",
    "Inaccessible": "This means actual access failure. External access was not attempted in this work, so this state was not assigned.",
    "Not applicable": "Used only with an application exception and reason based on the question scope.",
    "Conflicting data": "This requires actual comparison of materials; no new conflict judgment was made in this work.",
    "Insufficient evidence for the conditions": "This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade."
  },
  "requirements": [
    {
      "item_id": "N01",
      "question_type": "Evidence condition",
      "question": "Which allergic-rhinitis question is addressed?",
      "needed": "Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo",
      "role": "Required",
      "role_reason": "Material on Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original eligibility, intervention/comparator details, nasal-symptom/rescue-medication results and denominators are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N02",
      "question_type": "Evidence condition",
      "question": "Are ascorbic acid, salt and tablet composition known?",
      "needed": "Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing",
      "role": "Required",
      "role_reason": "Material on Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original product names, ingredients, salts, excipients and manufacturing records are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N03",
      "question_type": "Evidence condition",
      "question": "What is known about 1 g/day and actual exposure?",
      "needed": "Main comparison dose, frequency, actual use and adherence",
      "role": "Required",
      "role_reason": "Material on Main comparison dose, frequency, actual use and adherence is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Main comparison dose, frequency, actual use and adherence must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Dosing, product, frequency, adherence, actual use and discontinuation records are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N04",
      "question_type": "Evidence condition",
      "question": "Are the 1.5-year study-conduct period and individual dosing duration distinguished?",
      "needed": "Study-conduct period, individual exposure, follow-up and symptom-assessment timing",
      "role": "Required",
      "role_reason": "Material on Study-conduct period, individual exposure, follow-up and symptom-assessment timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Study-conduct period, individual exposure, follow-up and symptom-assessment timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original registration, recruitment/conduct dates, individual dosing, follow-up and assessment schedules are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N05",
      "question_type": "Evidence condition",
      "question": "Are adult diagnosis, baseline symptoms and seasonality known?",
      "needed": "Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity",
      "role": "Required",
      "role_reason": "Material on Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original diagnosis, selection/exclusion, baseline symptoms, season/environment, comorbidities and arm-composition tables are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N06",
      "question_type": "Evidence condition",
      "question": "What were the sugar-placebo and comparable-care conditions?",
      "needed": "Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication",
      "role": "Required",
      "role_reason": "Material on Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original placebo, packaging, allocation/masking, concomitant treatment, rescue medication and lifestyle-care records are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N07",
      "question_type": "Evidence condition",
      "question": "Is C alone separated from combined exercise, combinations and intravenous infusion?",
      "needed": "Original oral monotherapy contrast and separation of other interventions",
      "role": "Required",
      "role_reason": "Material on Original oral monotherapy contrast and separation of other interventions is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Original oral monotherapy contrast and separation of other interventions must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original arms/intervention conditions and a separately identifiable monotherapy contrast are needed. Unidentified reports are not invented. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N08",
      "question_type": "Evidence condition",
      "question": "Are the 40 people and arm-specific analysis denominators known?",
      "needed": "Overall size, arm allocation, analysis, completion and TNSS denominators",
      "role": "Required",
      "role_reason": "Material on Overall size, arm allocation, analysis, completion and TNSS denominators is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Overall size, arm allocation, analysis, completion and TNSS denominators must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original arm-specific flow, allocation, analysis, completion and endpoint denominators are needed. No new attrition count is calculated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N09",
      "question_type": "Evidence condition",
      "question": "Are randomization and masking correctly left unverified?",
      "needed": "Allocation sequence, concealment and participant/assessor masking",
      "role": "Required",
      "role_reason": "Material on Allocation sequence, concealment and participant/assessor masking is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Allocation sequence, concealment and participant/assessor masking must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original methods, registration, protocol and allocation/masking records are needed. No new official risk or certainty assessment is created. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N10",
      "question_type": "Evidence condition",
      "question": "What are the original total and individual nasal-symptom results?",
      "needed": "Between-group estimates for TNSS, obstruction, discharge and sneezing",
      "role": "Required",
      "role_reason": "Material on Between-group estimates for TNSS, obstruction, discharge and sneezing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Between-group estimates for TNSS, obstruction, discharge and sneezing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original endpoint definitions, between-group tables, baseline/change values, individual symptoms, denominators and assessment times are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N11",
      "question_type": "Evidence condition",
      "question": "Are rescue-medication outcomes distinguished from nasal symptoms?",
      "needed": "Rescue-medication type, rules, arm-specific use, denominators and timing",
      "role": "Required",
      "role_reason": "Material on Rescue-medication type, rules, arm-specific use, denominators and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Rescue-medication type, rules, arm-specific use, denominators and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original rescue-medication conditions, amounts/frequency, denominators, timing and result tables are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N12",
      "question_type": "Evidence condition",
      "question": "Are gaps in effect size, 95% CI and P retained?",
      "needed": "Exact effect, variance and uncertainty versus suitable placebo",
      "role": "Required",
      "role_reason": "Material on Exact effect, variance and uncertainty versus suitable placebo is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Exact effect, variance and uncertainty versus suitable placebo must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original values, variance, arm denominators, model and CI/P are needed. No new effect or interval is calculated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N13",
      "question_type": "Evidence condition",
      "question": "Are prespecified 1st TNSS and reporting hierarchy known?",
      "needed": "Prespecified plans for TNSS, signs, plasma C and assessment times",
      "role": "Required",
      "role_reason": "Material on Prespecified plans for TNSS, signs, plasma C and assessment times is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Prespecified plans for TNSS, signs, plasma C and assessment times must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original registration, protocol, analysis plan, endpoints/times and complete result tables are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N14",
      "question_type": "Evidence condition",
      "question": "What were symptom assessment, baseline adjustment and analysis sets?",
      "needed": "Scale, assessor, baseline scores, final/change values and estimand",
      "role": "Required",
      "role_reason": "Material on Scale, assessor, baseline scores, final/change values and estimand is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Scale, assessor, baseline scores, final/change values and estimand must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original assessments, times, baseline/adjustment, variance, allocation-based/completer analyses and statistical tables are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N15",
      "question_type": "Evidence condition",
      "question": "What is known about missingness, attrition and treatment changes?",
      "needed": "Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes",
      "role": "Required",
      "role_reason": "Material on Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original flow, exclusion reasons, treatment changes, missing-data handling and sensitivity material are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N16",
      "question_type": "Evidence condition",
      "question": "Are plasma C and histamine mechanisms distinguished from symptom effects?",
      "needed": "Separate comparisons for plasma C, histamine and clinical nasal symptoms",
      "role": "Supplementary",
      "role_reason": "Material on Separate comparisons for plasma C, histamine and clinical nasal symptoms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Separate comparisons for plasma C, histamine and clinical nasal symptoms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Direct nasal-symptom/rescue-medication comparisons and separate mechanistic-marker results are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N17",
      "question_type": "Evidence condition",
      "question": "Are population and denominators from the 2025 skin-test study kept separate?",
      "needed": "Skin-test entry, completion, arm/endpoint denominators and diagnosis",
      "role": "Supplementary",
      "role_reason": "Material on Skin-test entry, completion, arm/endpoint denominators and diagnosis is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Skin-test entry, completion, arm/endpoint denominators and diagnosis must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original population, diagnosis, allocation/completion, skin-endpoint analysis denominators and attrition records are needed. No new attrition count or total is calculated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N18",
      "question_type": "Evidence condition",
      "question": "Are histamine-wheal results retained accurately?",
      "needed": "Skin-wheal change in mm², original ±, P and timing",
      "role": "Supplementary",
      "role_reason": "Material on Skin-wheal change in mm², original ±, P and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Skin-wheal change in mm², original ±, P and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original dispersion definition, skin measurement, arms/times, denominators and intervals are needed. No new difference, CI or TNSS value is created. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N19",
      "question_type": "Evidence condition",
      "question": "Are dust-mite wheals also a separate skin outcome?",
      "needed": "Dust-mite wheal change, original ±, P and timing",
      "role": "Supplementary",
      "role_reason": "Material on Dust-mite wheal change, original ±, P and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Dust-mite wheal change, original ±, P and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original skin-result tables, units/dispersion, denominators, times, CI and prospective hierarchy are needed. Values are not converted into clinical effects. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N20",
      "question_type": "Evidence condition",
      "question": "Is a lack of skin-wheal difference kept separate from clinical replication or refutation?",
      "needed": "Directness boundary between surrogate markers and clinical nasal symptoms",
      "role": "Required",
      "role_reason": "Material on Directness boundary between surrogate markers and clinical nasal symptoms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Directness boundary between surrogate markers and clinical nasal symptoms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Direct replication evidence with the same population, oral monotherapy, clinical nasal symptoms and timing is needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N21",
      "question_type": "Evidence condition",
      "question": "Are the two reports distinguished from unique direct trials?",
      "needed": "Study families and overlap for the direct rhinitis comparison and skin-boundary report",
      "role": "Required",
      "role_reason": "Material on Study families and overlap for the direct rhinitis comparison and skin-boundary report is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Study families and overlap for the direct rhinitis comparison and skin-boundary report must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original registration, samples, centres/times and additional-report mapping are needed. Reports are not added to create participant or trial totals. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N22",
      "question_type": "Evidence condition",
      "question": "Are unverified bibliography details of the 2025 report retained?",
      "needed": "Original complete author list, PMID, DOI and registration identifiers",
      "role": "Supplementary",
      "role_reason": "Material on Original complete author list, PMID, DOI and registration identifiers is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Original complete author list, PMID, DOI and registration identifiers must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original complete bibliography, registration, methods and result materials are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N23",
      "question_type": "Evidence condition",
      "question": "Are the four company-involvement pathways known?",
      "needed": "Funding, manufacturer/product support, employee authors and conflicts of interest",
      "role": "Required",
      "role_reason": "Material on Funding, manufacturer/product support, employee authors and conflicts of interest is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Funding, manufacturer/product support, employee authors and conflicts of interest must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original funding, products, affiliations, conflict disclosures and team mapping are needed. Unverified involvement is not converted into no company involvement. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N24",
      "question_type": "Evidence condition",
      "question": "Are direct replication and persistent effects established?",
      "needed": "Unique replication trials with the same oral monotherapy and clinical endpoint",
      "role": "Supplementary",
      "role_reason": "Material on Unique replication trials with the same oral monotherapy and clinical endpoint is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Unique replication trials with the same oral monotherapy and clinical endpoint must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original trial families, products, duration, effects and denominators for the same question are needed. No new replication count is created. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N25",
      "question_type": "Evidence condition",
      "question": "Are harm collection, events and discontinuations known?",
      "needed": "Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort",
      "role": "Supplementary",
      "role_reason": "Material on Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original harm methods, events, discontinuations, omissions, comparator and period data are needed. Unread material is not treated as no harms. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N26",
      "question_type": "Evidence condition",
      "question": "Are harm denominators, exposure and comparators distinguished?",
      "needed": "Safety sets, actual use, events and individual exposure duration",
      "role": "Supplementary",
      "role_reason": "Material on Safety sets, actual use, events and individual exposure duration is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Safety sets, actual use, events and individual exposure duration must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Arm-specific safety denominators, actual dosing/discontinuation, events, exposure and comparator data are needed. Incidence rates are not calculated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N27",
      "question_type": "Evidence condition",
      "question": "Are stone, kidney-disease and iron-overload cautions distinguished from direct harms?",
      "needed": "Vulnerable populations, concomitant use, alternative causes and long-term/rare harms",
      "role": "Supplementary",
      "role_reason": "Material on Vulnerable populations, concomitant use, alternative causes and long-term/rare harms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Vulnerable populations, concomitant use, alternative causes and long-term/rare harms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Vulnerable groups, independent harm reports, exposure/denominators, concomitant use/alternative causes and event courses are needed. No new harm search or assessment is performed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N28",
      "question_type": "Evidence condition",
      "question": "Are historical abstract checking and PDF failure separated from current unread status?",
      "needed": "Historical access descriptions, current stored summaries and external-material status",
      "role": "Required",
      "role_reason": "Material on Historical access descriptions, current stored summaries and external-material status is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Historical access descriptions, current stored summaries and external-material status must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Current external acquisition, actual reading and review remain outstanding. Historical failure is not converted into current inaccessibility, or historical checking into current reading. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N29",
      "question_type": "Evidence condition",
      "question": "Are original Korean/English descriptions and empty correction records preserved?",
      "needed": "Complete Korean/English originals, empty corrections/detailed claims and original dates",
      "role": "Supplementary",
      "role_reason": "Material on Complete Korean/English originals, empty corrections/detailed claims and original dates is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on Complete Korean/English originals, empty corrections/detailed claims and original dates must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: New evidence, corrections and verdict changes require preservation of originals and separate event records. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N30",
      "question_type": "Evidence condition",
      "question": "Are original C46, EX/CX and I1 distinguished from production?",
      "needed": "C46, Caution, assessment values, original exception rationale and evidence date",
      "role": "Required",
      "role_reason": "Material on C46, Caution, assessment values, original exception rationale and evidence date is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.",
      "application_exception": "Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.",
      "criterion": "Original records on C46, Caution, assessment values, original exception rationale and evidence date must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.",
      "basis": "Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.",
      "condition_origin": "These existing conditions concern single-ingredient oral vitamin C, nasal symptoms and rescue medication in adults with allergic rhinitis. They link stored summaries and gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: New evidence, revised criteria and verdict changes are separate events. The existing date is not used as a current search or external-reading date. This records needed materials; no new research was executed."
    }
  ]
}